Loading...

Brilliant Violet 421™ anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_53-6.7_BV421_1_032911
C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD8a (clone 53-6.7) Brilliant Violet 421™. Quadrant gating was based on the rat IgG2a, κ Brilliant Violet 421™ isotype control.
  • 1_53-6.7_BV421_1_032911
    C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD8a (clone 53-6.7) Brilliant Violet 421™. Quadrant gating was based on the rat IgG2a, κ Brilliant Violet 421™ isotype control.
  • 2_IHC_53-6.7_BV421_071012
    BL6 mouse lymph nodes, fixed O/N in PLP, blocked with 10% rat serum, stained with CD8a-BV421 (red), B220-Alexa Fluor® 647 (blue), and TCRβ-Alexa Fluor® 488 (green) in 1% BSA and 0.1% Tween-20 in PBS. Images were acquired with an automated widefield microscope (Nikon Eclipse Ti) and a CCD camera (QImaging Retiga 2000R). Emitted light was collected through 440/40, 525/50, and 700/75 nm bandpass filters. Images provided by Ann Haberman and Christine Podolski, Yale University.
  • 35_Mouse_Spleen_CD4_CD8_IgD
    Confocal image of C57BL/6 mouse spleen sample acquired using the IBEX method of highly multiplexed antibody-based imaging: CD4 (cyan), CD8 (magenta), and IgD (blue) in Cycle 1. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
  • 40_Mouse_Thymus_CD8_CD11c
    Confocal image of C57BL/6 mouse thymus sample acquired using the IBEX method of highly multiplexed antibody-based imaging: CD8 (blue) in Cycle 2 and CD11c (magenta) in Cycle 3. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
  • 48_Mouse_Gut_EpCAM_CD8_CD31
    Confocal image of C57BL/6 mouse small intestine sample acquired using the IBEX method of highly multiplexed antibody-based imaging: EpCAM (magenta) in Cycle 1, CD8 (blue) in Cycle 1, and CD31 (green) in Cycle 2. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
  • 53_Mouse_Liver_CD8_CD44_NK1.1
    Confocal image of C57BL/6 mouse liver sample acquired using the IBEX method of highly multiplexed antibody-based imaging: CD8 (cyan) in Cycle 2, CD44 (blue) in Cycle 2, and NK1.1 (red) in Cycle 3. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
Compare all formats See Brilliant Violet 421™ spectral data See high resolution IBEX data...
Cat # Size Price Quantity Check Availability Save
100737 125 µL 132€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100753 50 µg 202€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100738 500 µL 300€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC - Verified

SB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed
  2. Yang J, et al. 2022. Mol Ther Nucleic Acids. 30:184. PubMed
  3. Balood M, et al. 2022. Nature. 611:405. PubMed
  4. Xu Y, et al. 2023. EMBO Rep. 24:e55503. PubMed
  5. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  6. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  7. Nettersheim FS, et al. 2023. Front Cardiovasc Med. 9:1076808. PubMed
  8. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  9. Vijver SV, et al. 2023. Front Immunol. 13:1100730. PubMed
  10. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  11. Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed
  12. Xiao R, et al. 2022. J Immunol. 208:2109. PubMed
  13. Balakrishnan PB, et al. 2022. Nano Res. 15:2300. PubMed
  14. Ho HM, et al. 2022. Pharmaceutics. 14:. PubMed
  15. Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed
  16. Florian DC, et al. 2023. Cancer Res Commun. 3:223. PubMed
  17. Yi J, et al. 2023. Nat Commun. 14:1941. PubMed
  18. Zhang AQ, et al. 2023. Nat Biomed Eng. . PubMed
  19. Wang X, et al. 2023. Nat Commun. 14:3440. PubMed
  20. Guo X, et al. 2023. Mol Immunol. 160:32. PubMed
  21. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  22. McNamara HA, et al. 2020. Cell Host Microbe. 572:28. PubMed
  23. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  24. Gabriely G, et al. 2021. iScience. 24:103347. PubMed
  25. Nguyen NDNT, et al. 2020. NPJ Vaccines. 5:7. PubMed
  26. Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed
  27. Groza D, et al. 2018. Oncoimmunology. 7:e1424676. PubMed
  28. Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed
  29. Lee J, et al. 2020. Gut Microbes. 1:. PubMed
  30. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  31. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  32. Stathopoulou C, et al. 2020. Immunity. 49(2):247-263.e7.. PubMed
  33. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  34. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  35. Pokrovskii M, et al. 2020. EMBO J. 39:e104159. PubMed
  36. Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed
  37. Franks SE, et al. 2019. J Immunol. 202:3381. PubMed
  38. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  39. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  40. Wang Y, et al. 2021. Cancer Cell. 39:1375. PubMed
  41. Helm M, et al. 2022. Life (Basel). 12:. PubMed
  42. Paprckova D, et al. 2022. Front Immunol. 13:1009198. PubMed
  43. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  44. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  45. Lees JG, et al. 2020. PLoS One. 15:e0238164. PubMed
  46. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  47. Ding Z, Dahlin J 2016. Sci Rep. 6:28290. PubMed
  48. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  49. Woodworth JS, et al. 2021. Nat Commun. 12:6658. PubMed
  50. Levine LS, et al. 2021. Immunity. 54(4):829-844.e5. PubMed
  51. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  52. Stokes J, et al. 2020. Oncoimmunology. 9:1758011. PubMed
  53. Miller IC, et al. 2021. Nature Biomedical Engineering. :. PubMed
  54. Köchl R, et al. 2020. Elife. 9:00. PubMed
  55. Wagle MV, et al. 2021. Nat Commun. 12:2782. PubMed
  56. Park D, et al. 2020. Cancer Res. 80:4172. PubMed
  57. Fulham MA, et al. 2019. Am J Physiol Cell Physiol. 317:C687. PubMed
  58. Fan Z, et al. 2020. EMBO Mol Med. 12:e11571. PubMed
  59. Hutter K, et al. 2020. FEBS J. . PubMed
  60. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  61. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  62. Lu X, et al. 2020. Sci Transl Med. 12:. PubMed
  63. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  64. Knizkova D, et al. 2022. Nat Immunol. 23:1644. PubMed
  65. Bambouskova M, et al. 2021. Cell Reports. 34(10):108756. PubMed
  66. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  67. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
  68. Sum E, et al. 2021. Clin Cancer Res. 27:4036. PubMed
  69. Siamishi I, et al. 2020. Cell Reports. 31(11):107756. PubMed
  70. Chen Z, et al. 2014. Cancer Immunol Res. 2:911. PubMed
  71. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  72. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  73. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  74. Sinclair LV, et al. 2020. Immunometabolism. 2:e200029. PubMed
  75. LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed
  76. Hu-Lieskovan S, et al. 2015. Sci Transl Med. 7:279. PubMed
  77. Ballet R, et al. 2014. PLoS Pathog. 10:1004550. PubMed
  78. Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed
  79. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  80. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  81. Giampazolias E, et al. 2021. Cell. . PubMed
  82. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  83. Dai Z, et al. 2022. Signal Transduct Target Ther. 7:85. PubMed
  84. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  85. Dong X, et al. 2022. Front Immunol. 13:896472. PubMed
  86. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  87. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  88. Klepsch V, et al. 2018. Nat Commun. 9:1538. PubMed
  89. Briukhovetska D, et al. 2020. Frontiers in Immunology. 1.428472222. PubMed
  90. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  91. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  92. Pavelko K, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01532. PubMed
  93. Heil J, et al. 2021. Nat Commun. 12:6963. PubMed
  94. Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed
  95. Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed
  96. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  97. Freed-Pastor WA, et al. 2021. Cancer Cell. 39:1342. PubMed
  98. Iwanami N, et al. 2020. iScience. 23:101260. PubMed
  99. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  100. Li Q, et al. 2022. J Biol Chem. :101753. PubMed
  101. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  102. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  103. Dammeijer F, et al. 2020. Cancer Cell. 38(5):685-700.e8. PubMed
  104. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  105. Young A, et al. 2017. Cancer Res. 77:4684. PubMed
RRID
AB_10897101 (BioLegend Cat. No. 100737)
AB_10897101 (BioLegend Cat. No. 100753)
AB_10897101 (BioLegend Cat. No. 100738)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD8alpha
Specificity Alt (DOES NOT SHOW ON TDS):
CD8a
App Abbreviation (DOES NOT SHOW ON TDS):
FC,IHC,SB
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 3    Revision Date: 04.20.2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account